← ANALYST RATINGS · TIPRANKS
Bioventus (BVS): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $17.50, the highest $19.00, the lowest $15.00. The average is +31.6% from the last price of $13.30.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Unknown Analyst | Cantor Fitzgerald | $15.00 | Buy | +12.8% | Reiterated | 17.08.26on TipRanks Aug 24 21:07 | −2.2%next day +3.7% · 5 days +2.2% | ↗ |
| Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% | Canaccord Genuity | $15.00 → $19.00+26.7% | Buy | +42.9% | Reiterated | 17.08.26on TipRanks 07:22 | −2.2%next day +3.7% · 5 days +2.2% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $15.50 → $17.50+12.9% | Buy | +31.6% | Reiterated | 06.08.26on TipRanks 12:11 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $15.50 → $17.50+12.9% | Buy | +31.6% | Reiterated | 06.08.26on TipRanks 11:41 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $14.00 → $16.00+14.3% | Hold | +20.3% | Reiterated | 06.08.26on TipRanks 11:41 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $15.50 → $17.50+12.9% | Buy | +31.6% | Reiterated | 06.08.26on TipRanks 11:41 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $15.50 → $17.00+9.7% | Buy | +27.8% | Reiterated | 06.08.26on TipRanks 11:41 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $15.50 → $17.00+9.7% | Buy | +27.8% | Reiterated | 06.08.26on TipRanks 11:41 | — | |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $16.00 → $18.00+12.5% | Buy | +35.3% | Assigned | 06.08.26on TipRanks 09:30 | −8.2%next day +0.4% · 5 days −1.9% | ↗ |
| Michael Petusky★★★★★★★★★★#4246 · hits 45% · avg +2.3% | Barrington | $14.00 → $18.00+28.6% | Buy | +35.3% | Reiterated | 06.08.26on TipRanks 08:06 | −8.2%next day +0.4% · 5 days −1.9% | ↗ |
| Lawrence Solow★★★★★★★★★★#3322 · hits 60% · avg +21.1% | CJS Securities | $14.00 | Buy | +5.3% | Initiated | 27.03.26on TipRanks 09:05 | −1.7%next day +0.6% · 5 days −3.0% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Bioventus
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $17.50 at a price of $13.63 (+28.4%); now: $17.50 at $13.30 (+31.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 2 | 2 | 1 | 0 | 0 |
| Buy | 7 | 7 | 8 | 8 | 7 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.15 (from $0.10 to $0.18). Last quarter: $0.22.
Sales
Next quarter’s sales estimate — $150M (from $148M to $151M). Last quarter: $153M.
Best top-analyst consensus in the sector · Healthcare
About Bioventus
- CEO: Robert Claypoole
- Employees: 950
- 4721 Emperor Boulevard, Durham, NC, 27703, US
- www.bioventus.com
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Data from the stock’s TipRanks forecast page, read 199 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗